Lantheus HoldingsLNTH -1.11%82 3-Year ROIIC % is 24.05 as of Dec. 2025, which is 227% above its 10-year median of 7.35. GuruFocus rates LNTH with a GF Score™ of 82/100 and a GF Value™ of $90.74 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 944 Drug Manufacturers companies, Lantheus Holdings ranks better than 73.52% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Lantheus Holdings's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 24.05%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Lantheus Holdings's 3-Year ROIIC % or its related term are showing as below:
LNTH's 3-Year ROIIC % is ranked better than 73.52% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.635
vs LNTH: 24.05
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Lantheus Holdings 3-Year ROIIC % Related Terms
Lantheus Holdings 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Lantheus Holdings's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LNTH vs LQDA, HIMS, AMRX: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantheus Holdings 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's 3-Year ROIIC % falls into.
Lantheus Holdings's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 234.8705637 (Dec. 2025) - 36.195 (Dec. 2022) )
/
( 1639.88 (Dec. 2025) - 813.909 (Dec. 2022) )
=
198.6755637
/
825.971
=
24.05%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Lantheus Holdings (LNTH) has a 3-Year ROIIC % of 24.05 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Lantheus Holdings and its competitors. This is 227% above median its historical median of 7.35. According to the industry distribution chart, Lantheus Holdings ranks #250 out of 944 companies in the Drug Manufacturers industry, placing it in the top 26.5%.
Is Lantheus Holdings' 3-Year ROIIC % too high?
Lantheus Holdings' current 3-Year ROIIC % of 24.05 is 227% above median its 10-year median of 7.35. The Drug Manufacturers industry median 3-Year ROIIC % is 3.64. Lantheus Holdings' value of 24.05 is 561.6% above this industry median. Based on the distribution chart, Lantheus Holdings ranks #250 out of 944 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Lantheus Holdings has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' 3-Year ROIIC % compare to LQDA and HIMS?
According to the Drug Manufacturers industry distribution chart, Lantheus Holdings ranks #250 out of 944 companies for 3-Year ROIIC %. This puts Lantheus Holdings in the upper half of its industry. The industry median 3-Year ROIIC % is 3.64. Lantheus Holdings' value of 24.05 is 561.6% above this benchmark. While the company's 10-year median is 7.35 vs. the industry median of 3.64, Lantheus Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lantheus Holdings's current 3-Year ROIIC % of 24.05 is 561.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Lantheus Holdings and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lantheus Holdings's current 3-Year ROIIC % is 24.05, which is 227% above median its own 10-year median of 7.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (LNTH) is currently considered Modestly Overvalued. The stock's GF Value™ is $90.74, compared to a current price of $105.57 — trading 16.3% above its estimated fair value. The current 3-Year ROIIC % is 24.05, which is 227% above median its 10-year median of 7.35 and 561.6% above the Drug Manufacturers industry median of 3.64. Lantheus Holdings' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Lantheus Holdings (LNTH), the current 3-Year ROIIC % is 24.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lantheus Holdings (LNTH) Overvalued in 2026?
Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued.
The current stock price of $105.57 is trading 16.3% above its estimated GF Value™ of $90.74.
GuruFocus considers Lantheus Holdings to be Modestly Overvalued.
Key valuation signals for LNTH:
3-Year ROIIC %: 24.05 (227% above median its 10-year median of 7.35)
GF Value™: $90.74 vs. price of $105.57 (16.3% above fair value)
Industry Position: 561.6% above the Drug Manufacturers median (#250 of 944)
No single metric tells the full story. See the LNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
82GF Score
Get the complete analysis for LNTH
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LNTH has been successfully added to your 
